A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Cynthia McLaughlin
Cynthia McLaughlin
Cynthia McLaughlin
Michael Rose
| Share Statistics | NKTR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,412.2 | $626.3 | 57% |
|
| Shares Out (Mil) | 33.1 | 43.4 | 39% |
|
| Institutional Ownership | 99.6% | 83.9% | 91% |
|
| Float (Mil) | 28.5 | 45.7 | 35% |
|
| Beta | 1.16 | 0.73 | 69% |
|
| Avg Daily Volume (000s) | 564 | 309 | 62% |
|
| Price Change (52-week) |
45.5% | 66.6% | 80% |
|
| Growth | NKTR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (18.4%) | 6.7% | 3% |
|
| Net Income (5yr) | 18.1% | (1.6%) | 70% |
|
| EPS (5yr) | 23.6% | 15.1% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.1%) | (15.0%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 5 | |
| Current EPS | ($2.258) | ($8.465) | ($10.844) | |
| Month Ago EPS | ($0.515) | ($9.543) | ($11.872) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.515) | ($9.543) | ($12.563) | |
| Year/Year Chg | 83.7% | (13.0%) | 22.1% | |
| Financials | NKTR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $55 | $317 | 21% |
|
| Net Income (TTM) (Mil) | ($157) | ($11) | 8% |
|
| EPS (TTM) | ($6.468) | ($0.700) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($234) | ($6) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $6 | 35% |
|
| Long-Term Debt (Q1) (Mil) | $113 | $6 | 45% |
|
| Enterprise Value (Q1) (Mil) | $1,945 | $525 | 48% |
|
| Valuation | NKTR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.67 | 2.69 | 62% |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NKTR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 68.8% | 96% |
|
| Net Margin | (287.8%) | (1.4%) | 3% |
|
| ROA | (24.1%) | (24.1%) | 19% |
|
| ROE | (35.8%) | (21.4%) | 18% |
|
| Liabilities to Assets | 17.5% | 33.1% | 11% |
|
| F-Score | 3 | 3 | 18% |
|
Nektar Therapeutics did not pass any screens on 9/10/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
